Skip to content

BIOTRICITY INC.: 10-K filed 2018-07-13

What BIOTRICITY INC. reported in its annual report filed 2018-07-13 (fiscal FY 2018): 18 published measures, 38 facts as tagged in accession 0001511164-18-000427.

This filing

Form
10-K (annual report)
Filed
2018-07-13
Fiscal period
fiscal FY 2018
Accession
0001511164-18-000427 on SEC EDGAR

Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All BIOTRICITY INC. filings.

Reported measures

Total assets

Resources recognized on the balance sheet. Book assets are not the market value of the business.

PeriodValueUnitDays
At 2018-03-31929,426USD
At 2017-03-31473,512USD

Total liabilities

Recognized obligations at the reporting date. The definition and scope differ from interest-bearing debt.

PeriodValueUnitDays
At 2018-03-31756,179USD
At 2017-03-314,858,328USD

Stockholders equity

The reported residual interest after liabilities. It is an accounting amount, not market capitalization.

PeriodValueUnitDays
At 2018-03-31173,247USD
At 2017-03-31-4,384,816USD
At 2016-03-31-2,569,979USD

Cash and cash equivalents

Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.

PeriodValueUnitDays
At 2018-03-31843,643USD
At 2017-03-31424,868USD
At 2016-03-3153,643USD

Net income or loss

Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.

PeriodValueUnitDays
2017-04-01 to 2018-03-31-8,623,738USD365
2016-04-01 to 2017-03-31-7,809,291USD365

Operating cash flow

Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.

PeriodValueUnitDays
2017-04-01 to 2018-03-31-4,874,535USD365
2016-04-01 to 2017-03-31-3,748,865USD365

Financing cash flow

Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.

PeriodValueUnitDays
2017-04-01 to 2018-03-315,289,281USD365
2016-04-01 to 2017-03-313,967,504USD365

Retained earnings or deficit

Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.

PeriodValueUnitDays
At 2018-03-31-26,447,430USD
At 2017-03-31-18,307,215USD

Share-based compensation expense

Reported noncash expense for share-based payment arrangements. Noncash treatment does not mean the awards have no economic cost to shareholders.

PeriodValueUnitDays
2017-04-01 to 2018-03-311,002,201USD365
2016-04-01 to 2017-03-31626,136USD365

Current assets

Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.

PeriodValueUnitDays
At 2018-03-31896,426USD
At 2017-03-31440,512USD

Operating expenses

Recurring operating costs under this accounting concept, generally excluding production costs included in cost of sales. Check filing presentation before combining expense subtotals.

PeriodValueUnitDays
2017-04-01 to 2018-03-317,723,734USD365
2016-04-01 to 2017-03-315,942,170USD365

Research and development expense

Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.

PeriodValueUnitDays
2017-04-01 to 2018-03-311,762,561USD365
2016-04-01 to 2017-03-311,138,252USD365

Common shares outstanding

Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.

PeriodValueUnitDays
At 2018-03-3123,713,602shares
At 2017-03-3118,075,841shares

Additional paid-in capital

Capital contributed above par value under this concept. It records historical contributions, not the current value of the equity or cash on hand.

PeriodValueUnitDays
At 2018-03-3127,161,984USD
At 2017-03-3114,308,583USD

Accumulated other comprehensive income or loss

Cumulative other comprehensive items after tax, such as translation and unrealized hedging or securities effects. These amounts have not passed through net income.

PeriodValueUnitDays
At 2018-03-31-643,129USD
At 2017-03-31-413,384USD

Accrued current liabilities

Current obligations accrued for goods and services received but not yet invoiced or paid. This is one component of current liabilities, not all short-term obligations.

PeriodValueUnitDays
At 2018-03-31208,321USD
At 2017-03-31271,266USD

Profit or loss including noncontrolling interests

Net income or loss including the portion attributable to noncontrolling interests. It can differ from the net income attributable to the parent that per-share figures use.

PeriodValueUnitDays
2017-04-01 to 2018-03-31-8,623,738USD365
2016-04-01 to 2017-03-31-7,809,290USD365

General and administrative expense

General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.

PeriodValueUnitDays
2017-04-01 to 2018-03-315,961,173USD365
2016-04-01 to 2017-03-314,803,918USD365

Inspect the source

Entity
BIOTRICITY INC. / CIK 0001630113
Captured
2026-09-21T17:22:14.606Z
SEC response SHA-256
de56e3354d4180362d8bf36a6dd02ff7fd0db9690bc31c81e452959deb9a8d37

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

Read the published dataset with Python
import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0001630113.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))